Results overview: Found 6 records in 0.02 seconds.
Articles, 5 records found
Research literature, 1 records found
Articles 5 records found  
1.
13 p, 2.2 MB Monitoring EGFR -T790M mutation in serum/plasma for prediction of response to third-generation EGFR inhibitors in patients with lung cancer / Morán, Teresa (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Felip, Eudald (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Bosch-Barrera, Joaquim (Hospital Universitari de Girona Doctor Josep Trueta) ; de Aguirre, Itziar (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Ramirez, Jose Luis (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Mesia, Carles (Medical Oncology Department, Catalan Institute of Oncology - Hospital Duran i Reynalds, l'Hospitalet de Llobregat, Barcelona, Spain) ; Carcereny, Enric (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Roa, Diana (Hospital Universitari de Girona Doctor Josep Trueta) ; Sais, Elia (Hospital Universitari de Girona Doctor Josep Trueta) ; García García, Yolanda (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ; Blanco, Remei (Consorci Sanitari de Terrassa. Departament d'Oncologia) ; Sanchez, Silvia (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Villacorta, Claudia Rosa (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Queralt, C. (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Velarde, Jose María (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Rosell, Rafael (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Universitat Autònoma de Barcelona
Osimertinib is efficacious in lung cancer patients with epidermal growth factor receptor (EGFR) mutations and acquired resistance (AR) to EGFR tyrosine kinase inhibitors due to EGFR -T790M mutation (T790M). [...]
2018 - 10.18632/oncotarget.25478
Oncotarget, Vol. 9 (june 2018) , p. 27074-27086  
2.
1 p, 789.3 KB Correction : Monitoring EGFR -T790M mutation in serum/plasma for prediction of response to third-generation EGFR inhibitors in patients with lung cancer / Morán, Teresa (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Felip, Eudald (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Bosch-Barrera, Joaquim (Hospital Universitari de Girona Doctor Josep Trueta) ; de Aguirre, Itziar (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Ramirez, Jose Luis (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Mesia, Carles (Medical Oncology Department, Catalan Institute of Oncology - Hospital Duran i Reynalds, l'Hospitalet de Llobregat, Barcelona, Spain.) ; Carcereny, Enric (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Roa, Diana (Hospital Universitari de Girona Doctor Josep Trueta) ; Sais, Elia (Hospital Universitari de Girona Doctor Josep Trueta) ; García García, Yolanda (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ; Blanco, Remei (Consorci Sanitari de Terrassa. Departament d'Oncologia) ; Sanchez, Silvia (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Villacorta, Claudia Rosa (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Queralt, C. (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Velarde, Jose María (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Rosell, Rafael (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Universitat Autònoma de Barcelona
2019 - 10.18632/oncotarget.26855
Oncotarget, Vol. 10 (april 2019) , p. 2576  
3.
17 p, 2.4 MB Tumor expression of cyclin-dependent kinase 5 (Cdk5) is a prognostic biomarker and predicts outcome of oxaliplatin-treated metastatic colorectal cancer patients / Ruiz de Porras, V. (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Bystrup, Sara (Institut Germans Trias i Pujol) ; Cabrero de las Heras, Sara (Institut Germans Trias i Pujol) ; Musulén, Eva (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Palomero, L. (Institut d'Investigació Biomèdica de Bellvitge) ; Alonso, M.H. (Universitat de Barcelona. Departament de Ciències Clíniques) ; Nieto Raya, Rocio (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Arango, Diego (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Moreno, V. (Universitat de Barcelona. Departament de Ciències Clíniques) ; Queralt, C. (Institut Germans Trias i Pujol) ; Manzano Mozo, José Luís (Institut Germans Trias i Pujol) ; Layos, Laura (Institut Germans Trias i Pujol) ; Bugés, Cristina (Institut Germans Trias i Pujol) ; Martínez Balibrea, Eva (Institut Germans Trias i Pujol) ; Universitat Autònoma de Barcelona
In recent years, an increasing number of studies have shown that elevated expression of cyclin dependent kinase (Cdk5) contributes to the oncogenic initiation and progression of many types of cancers. [...]
2019 - 10.3390/cancers11101540
Cancers, Vol. 11 Núm. 10 (october 2019) , p. 1540  
4.
12 p, 1.4 MB Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC / Chaib, Imane (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Karachaliou, Niki (Instituto Oncológico Dr. Rosell, Institut Universitari Quirón-Dexeus) ; Pilotto, Sara (Medical Oncology, Azienda Ospedaliera Universitaria Integrata, University of Verona) ; Codony-Servat, Jordi (Pangaea Biotech, Laboratory of Molecular Biology) ; Cai, Xueting (Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine) ; Li, Xuefei (Shangai Pulmonary Hospital, Tongji University School of Medicine, Shangai) ; Drozdowskyj, Ana (Pivotal, Madrid) ; Codony Servat, Carles (Pangaea Biotech, Laboratory of Molecular Biology) ; Yang, Jie (Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine) ; Hu, Chunping (Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine) ; Cardona, Andrés Felipe (Clinica del Country, Bogotá) ; Lopez Vivanco, Guillermo (Hospital Universitario de Cruces (Barakaldo, País Basc)) ; Vergnenegre, Alain (Service de Pathologie Respiratoire et d'Allergologie, CHU, Limoges France) ; Jose Miguel Sanchez (Hospital Universitario de la Princesa (Madrid)) ; Provencio, Mariano (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ; Marinis, Filippo de (Hospital Universitario de Cruces (Barakaldo, País Basc)) ; Passaro, Antonio (Hospital Universitario de Cruces (Barakaldo, País Basc)) ; Carcereny, Enric (Service de Pathologie Respiratoire et d'Allergologie, CHU, Limoges France) ; Reguart, Noemi (Hospital Clínic i Provincial de Barcelona) ; Garcia Campelo, Charo (Hospital Universitario de la Princesa (Madrid)) ; Teixido, Cristina (Pangaea Biotech, Laboratory of Molecular Biology) ; Sperduti, Isabella (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ; Rodriguez, Sonia (Pangaea Biotech, Laboratory of Molecular Biology) ; Lavazzi, Chiara (Hospital Universitario de Cruces (Barakaldo, País Basc)) ; Verlicchi, Alberto (Hospital Clínic i Provincial de Barcelona) ; Aguirre, Itziar de (Institut Germans Trias i Pujol) ; Queralt, Cristina (Institut Germans Trias i Pujol) ; Wei, Jia (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Estrada-Tejedor, Roger (WVU Cancer Institute, West Virginia University, Morgantown, WV, USA) ; Puig de la Bellacasa, Raimon (WVU Cancer Institute, West Virginia University, Morgantown, WV, USA) ; Ramirez, Jose Luis (Institut Germans Trias i Pujol) ; Jacobson, Kirstine (WV Clinical and Translational Science Institute, Morgantown, WV, USA) ; Ditzel, Henrik J. (WV Clinical and Translational Science Institute, Morgantown, WV, USA) ; Santarpia, Mariacarmela (UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA) ; Viteri, Santiago (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Molina, Miguel Angel (Pangaea Biotech, Laboratory of Molecular Biology) ; Zhou, Caicun (Shangai Pulmonary Hospital, Tongji University School of Medicine, Shangai) ; Cao, Peng (Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, China) ; Ma, Patrick C. (WVU Cancer Institute, West Virginia University, Morgantown, WV, USA) ; Bivona, Trever G. (UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA) ; Rosell, Rafael (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Background: The efficacy of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in EGFR-mutant non- small cell lung cancer (NSCLC) is limited by adaptive activation of cell survival signals. [...]
2017
Journal of the National Cancer Institute, Vol. 109 (september 2017) , p. 1-12  
5.
6 p, 52.6 KB Noves aportacions a la flora de la serra de Montsià (comarca del Montsià. NE de la península Ibèrica) / Hinojosa Queralt, Carlos
Aquest article aporta la localització de noves espècies de plantes vasculars a la serra de Montsià (Montsià), fins ara no citades d'aquest espai natural, i noves localitzacions d'espècies recentment citades en diversos treballs de recerca. [...]
The present article contributes to the new species location wich have not been quote previously in the Serra de Montsià (Montsià), whereas new locations of species quoted recently in several searching works. [...]

2009
Orsis, Vol. 24 (2009) , p. 101-106  

Research literature 1 records found  
1.
303 p, 7.1 MB Estudi de les mutacions del gen EGFR en pacients d'estadis avançats per CPCNP / Queralt Herrero, Cristina ; Rosell Costa, Rafael, dir. ; Tarón Roca, Miquel, dir. ; Universitat Autònoma de Barcelona. Departament de Medicina
El carcinoma de pulmó de cèl·lula no petita (CPCNP) és un dels tumors més freqüents en la població caucàsica en què la histologia més comuna és l'adenocarcinoma. En diversos estudis clínics es va observar que un subgrup de pacients amb CPCNP avançat, amb unes característiques molt concretes (sexe femení, d'histologia adenocarcinoma i no fumador), es beneficiaven del tractament amb uns inhibidors de l'activitat tirosina quinasa (ITQ) d'EGFR (Epidermal Growth Factor Receptor). [...]
Non-small-cell lung cancer (NSCLC) is a major cause of death from cancer in the Caucasian population. Some clinical studies of tyrosine kinase inhibitors (TKIs) that target the epidermal growth factor receptor (EGFR) gene in patients with advanced NSCLC showed that some patients with clinical and pathological factors -such as female sex, adenocarcinoma histology (the most frequent histology in NSCLC) and never smoker status- experienced rapid responses. [...]

[Barcelona] : Universitat Autònoma de Barcelona, 2014  

See also: similar author names
2 Queralt, Cristina
Interested in being notified about new results for this query?
Set up a personal email alert or subscribe to the RSS feed.